India: brewing second wave overshadows the outlook
India: brewing second wave overshadows the outlook
India’s economy bounced back quickly after the stringent lockdown in March last year. GDP growth actually returned to positive territory in the final quarter of last year, rising 0.4% year-on-year (y/y). The rebound was partly driven by India’s apparent success in controlling Covid-19, enabling the economy to largely re-open.
After peaking in September, coronavirus cases in India came down significantly in the last few months of 2020. This was puzzling in itself as there were no new restrictions on activity, leading many analysts with little choice but to point to herd immunity. Irrespective of how it was achieved, the news provided a welcome boost to the growth outlook. The consensus economic growth forecast has increased to 9.3% y/y for this year.
However, over the past month we have become increasingly concerned over a brewing second wave of the pandemic in India. Especially as the vaccination programme has got of to an underwhelming start.
India behind in the vaccine race
India is lagging behind in the vaccine race, relative to other emerging markets. Granted, this is partly because of its vast population of 1.4 billion people, but the government is also falling short of its own target of vaccinating 300 million people – or one fifth of the population - by August.
The problem has been demand. Uptake of vaccines has been disappointing, and so far only 3.3% of the population have had their first dose.
The stark rise in daily new cases Covid-19 in recent weeks, highlighted in the chart below, suggests investors can no longer brush aside the slow vaccine roll-out. New cases have mainly come from Mumbai’s state of Maharashtra (14% GDP), which has accounted for over half the new infections. But other states have also experienced a significant rise in cases including Punjab (2.8% GDP), Madhya Pradesh (3.6% GDP) and Karnataka (7.8% GDP), the home of technology hub Bangalore.
Prime Minister Modi was quick to speak to Chief Ministers, as the heads of the state governments are known, last week. Modi emphasised the need to step up testing and ramp up the speed and efficacy of the vaccination programme.
As a key global producer of vaccines, this is already having implications for the supply of vaccines for the rest of the world. Vaccine delivery to the UK and Brazil were delays and now, India has announced that it is temporarily banning all exports of the Oxford-AstraZeneca coronavirus vaccine. This is expected to last until the end of April.
What does this mean for economic growth?
Tighter restrictions, including night curfews, which have been introduced by state governments in Covid-19 hotspots, are likely to have a detrimental impact on growth. As a result, we now see downside risk to the 11% figure we had pencilled in for this year.
The impact on growth from the additional restrictions announced so far should be reasonably contained. But the risk of more widespread lockdowns is now elevated, and would require a significant downward revision to our GDP growth forecast for this year.
Low level activity data – such as trade, vehicle sales, steel and cement production – suggest that growth already slowed slightly in January, as the chart below shows.
The second wave and risk of further restrictions will also likely make the Reserve Bank of India (RBI) very uncomfortable. The initial lockdowns proved inflationary, as supply side constraints resulted in cost-push inflation.
The RBI is already faced with rising core inflation is rising and higher commodity prices and are yet to fully feed through to inflation. However, it is likely to focus on any detrimental growth impact and delay its planned withdrawal of liquidity.
What does this mean for investors?
For equity investors, the downside to GDP growth has implications for company earnings, which have a reasonable relationship with domestic economic activity, as the next chart illustrates. This stems from India having a relatively domestic equity market, with companies generating around three-quarters of revenue in country.
For now though, our indicator suggests earnings should continue to improve in the short term, and will benefit from base-effects in the second quarter.
The backdrop is one where India’s valuation is one of the highest in emerging markets, as shown below. From a top-down perspective, the price tag attached to India’s equity market is underpinned by India’s long-run growth outlook. This is clear from the relationship between the price-to-earnings ratio and the IMF’s potential growth estimate.
In our previous work, we found that India’s potential growth rate is likely somewhat lower that the IMF estimate; around 6%. So despite the latest budget, which includes measures to improve medium term growth, India’s valuation is still a challenge for equity investors.
The situation is clearly rapidly evolving, but a second wave provides downside risk to growth and may force investors to take another look at the high valuation hurdle for Indian equities. Meanwhile, more lockdowns would likely force the RBI to delay any withdrawal of liquidity and any supply driven inflation would be unwelcome for India’s macroeconomic stability.
- China: the most radical climate reformer of all?
- Sustainable Investment Report Q2 2021: active ownership and the voting season in another year of virtual AGMs
- Inescapable Truths update: which trends have been strengthened or challenged by Covid-19?
- Video – Olympian Hannah Mills on the plastics crisis: how sport can drive change – and investment can too
- What is driving angst in the Andes?
- The pros, cons and incentives behind the SPAC-craze sweeping markets
Important information: The views and opinions contained herein are those of the author(s) on this page, and may not necessarily represent views expressed or reflected in other Schroders communications, strategies or funds. This article is intended to be for information purposes only and it is not intended as promotional material in any respect. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The material is not intended to provide, and should not be relied on for, accounting, legal or tax advice, or investment recommendations. Information herein is believed to be reliable but Schroders does not warrant its completeness or accuracy. No responsibility can be accepted for errors of fact or opinion. Reliance should not be placed on the views and information in the document when taking individual investment and/or strategic decisions. Past performance is not a reliable indicator of future results, prices of shares and the income from them may fall as well as rise and investors may not get back the amount originally invested. Issued by Schroder Investment Management Limited, 31 Gresham Street, London EC2V 7QA, which is authorised and regulated by the Financial Conduct Authority. For your security, communications may be taped or monitored.